TY - JOUR AU - Smolensky, Dmitriy AU - Rathore, Kusum AU - Cekanova, Maria PY - 2015 DA - 2015/11/23 TI - Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro JO - BMC Cancer SP - 927 VL - 15 IS - 1 AB - Doxorubicin (Dox) is widely used to treat progressed bladder cancer after transurethral resection. The use of Dox-chemotherapy has been limited due to induced drug resistance and cumulative cardiotoxic effects. N-benzyladriamycin-14-valerate (AD198), a novel derivative of Dox, has a potential to become a more effective treatment than Dox by overcoming drug resistance and cardio-toxicity as shown in the rodent model of lymphoma in vivo. The purpose of this study was to compare the efficacy of Dox and AD198 and explore their mechanisms in inhibition on human bladder cancer cells in vitro. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-015-1930-5 DO - 10.1186/s12885-015-1930-5 ID - Smolensky2015 ER -